837 related articles for article (PubMed ID: 35403948)
41. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.
Messori A; Rivano M; Mengato D; Chiumente M
Cureus; 2022 Dec; 14(12):e33169. PubMed ID: 36726938
[TBL] [Abstract][Full Text] [Related]
42. Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
Wang YW; Tsai XC; Hou HA; Tien FM; Liu JH; Chou WC; Ko BS; Chen YW; Lin CC; Cheng CL; Lo MY; Lin YC; Lu LC; Wu SJ; Kuo SH; Hong RL; Huang TC; Yao M
Ann Hematol; 2022 Feb; 101(2):349-358. PubMed ID: 34766217
[TBL] [Abstract][Full Text] [Related]
43. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
44. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
45. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
Lu Q; Huang H; Tang S; Wang Y; Yang DH
Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
[TBL] [Abstract][Full Text] [Related]
46. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Czuczman MS; Trněný M; Davies A; Rule S; Linton KM; Wagner-Johnston N; Gascoyne RD; Slack GW; Brousset P; Eberhard DA; Hernandez-Ilizaliturri FJ; Salles G; Witzig TE; Zinzani PL; Wright GW; Staudt LM; Yang Y; Williams PM; Lih CJ; Russo J; Thakurta A; Hagner P; Fustier P; Song D; Lewis ID
Clin Cancer Res; 2017 Aug; 23(15):4127-4137. PubMed ID: 28381416
[No Abstract] [Full Text] [Related]
47. Tafasitamab: First Approval.
Hoy SM
Drugs; 2020 Nov; 80(16):1731-1737. PubMed ID: 32946059
[TBL] [Abstract][Full Text] [Related]
48. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J; Abrisqueta P; Andre M; Gaidano G; Gonzales-Barca E; Jurczak W; Kalakonda N; Liberati AM; Maddocks KJ; Menne T; Nagy Z; Tournilhac O; Kuffer C; Bakuli A; Amin A; Gurbanov K; Salles G
Haematologica; 2024 Feb; 109(2):553-566. PubMed ID: 37646664
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Kambhampati S; Saumoy M; Schneider Y; Pak S; Budde LE; Mei MG; Siddiqi T; Popplewell LL; Wen YP; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
Blood; 2022 Dec; 140(25):2697-2708. PubMed ID: 35700381
[TBL] [Abstract][Full Text] [Related]
50. Diffuse large B-cell lymphoma: new targets and novel therapies.
Cheson BD; Nowakowski G; Salles G
Blood Cancer J; 2021 Apr; 11(4):68. PubMed ID: 33820908
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
Arcari A; Chiappella A; Spina M; Zanlari L; Bernuzzi P; Valenti V; Tani M; Marasca R; Cabras MG; Zambello R; Santagostino A; Ilariucci F; Carli G; Musto P; Savini P; Marino D; Ghio F; Gentile M; Cox MC; Vallisa D
Leuk Lymphoma; 2016 Aug; 57(8):1823-30. PubMed ID: 26666433
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States.
Matasar M; Sanchez Alvarez J; Parisé H; Zuk E; Di Maio D; Shapouri S; Kim E; Lin SW
J Med Econ; 2024; 27(1):766-776. PubMed ID: 38712895
[TBL] [Abstract][Full Text] [Related]
53. Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis.
Moore DC; Eagers KA; Janes A; Pineda-Roman M
J Oncol Pharm Pract; 2023 Jan; 29(1):239-241. PubMed ID: 35585701
[TBL] [Abstract][Full Text] [Related]
54. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Avivi I; Perry C; Segman Y; Amit O; Bar-On Y; Katz OB; Gold R; Ribakovsky E; Avigdor A; Vainstein V; Goldschmidt N; Ringelstein-Harlev S; Horowitz NA; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Vezker M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Luttwak E; Herishanu Y; Ram R
Ann Hematol; 2022 Apr; 101(4):755-762. PubMed ID: 35083525
[TBL] [Abstract][Full Text] [Related]
55. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Malecek MK; Watkins MP; Bartlett NL
Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753
[TBL] [Abstract][Full Text] [Related]
56. Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world.
Ionescu-Ittu R; Shang A; Velde NV; Guerin A; Lin Y; Shi L; Shi S; Qayum N
J Comp Eff Res; 2019 Oct; 8(13):1067-1075. PubMed ID: 31452397
[No Abstract] [Full Text] [Related]
57. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H; Chevrier M; Laadhari M; Chinot O; Choquet S; Moluçon-Chabrot C; Beauchesne P; Gressin R; Morschhauser F; Schmitt A; Gyan E; Hoang-Xuan K; Nicolas-Virelizier E; Cassoux N; Touitou V; Le Garff-Tavernier M; Savignoni A; Turbiez I; Soumelis V; Houillier C; Soussain C
Ann Oncol; 2019 Apr; 30(4):621-628. PubMed ID: 30698644
[TBL] [Abstract][Full Text] [Related]
58. United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
Tarantelli C; Bertoni F
Br J Haematol; 2022 Oct; 199(2):169-170. PubMed ID: 35917107
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.
Mizuoka T; Sakamaki H; Fuji S; Saito S; Murata T; Ohno S; Inubashiri N; Oshima T; Yamamoto K
J Med Econ; 2023; 26(1):1122-1133. PubMed ID: 37656225
[TBL] [Abstract][Full Text] [Related]
60. Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Majer I; van de Wetering G; Polanyi Z; Krishna A; Gray E; Roy A
Appl Health Econ Health Policy; 2017 Feb; 15(1):45-55. PubMed ID: 27550239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]